Profound Medical Upsizes Private Placement to $6.45M, Closes $36M Direct Offer
Profound Medical Corp. upsizes its private placement to $6.45 M, bolstering sales, R&D, and pipeline growth for localized prostate cancer treatments.
2 minutes to read
Profound Medical Corp
Profound Medical Corp Surges Back: Cutting‑Edge Prostate Cancer Tech Drives Toronto Stock Gains
Profound Medical Corp: Revolutionizing localized prostate cancer treatment with cutting‑edge tech, strong market recovery, and a global focus on innovation.
2 minutes to read